DK2542260T3 - Recombinantly weakening parvovirus - Google Patents

Recombinantly weakening parvovirus Download PDF

Info

Publication number
DK2542260T3
DK2542260T3 DK11706253.9T DK11706253T DK2542260T3 DK 2542260 T3 DK2542260 T3 DK 2542260T3 DK 11706253 T DK11706253 T DK 11706253T DK 2542260 T3 DK2542260 T3 DK 2542260T3
Authority
DK
Denmark
Prior art keywords
parvovirus
type
dogs
dna
virus
Prior art date
Application number
DK11706253.9T
Other languages
Danish (da)
English (en)
Inventor
Norman Spibey
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Application granted granted Critical
Publication of DK2542260T3 publication Critical patent/DK2542260T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14361—Methods of inactivation or attenuation
    • C12N2750/14362—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK11706253.9T 2010-03-05 2011-03-03 Recombinantly weakening parvovirus DK2542260T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31103210P 2010-03-05 2010-03-05
EP10155646 2010-03-05
PCT/EP2011/053164 WO2011107534A1 (en) 2010-03-05 2011-03-03 Recombinant attenuated parvovirus

Publications (1)

Publication Number Publication Date
DK2542260T3 true DK2542260T3 (en) 2016-06-06

Family

ID=42562704

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11706253.9T DK2542260T3 (en) 2010-03-05 2011-03-03 Recombinantly weakening parvovirus

Country Status (10)

Country Link
US (1) US9234182B2 (enExample)
EP (1) EP2542260B1 (enExample)
JP (3) JP6200155B2 (enExample)
CN (1) CN102791288B (enExample)
AU (1) AU2011222910B2 (enExample)
CA (1) CA2790653C (enExample)
DK (1) DK2542260T3 (enExample)
ES (1) ES2566033T3 (enExample)
RU (1) RU2527157C2 (enExample)
WO (1) WO2011107534A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107534A1 (en) * 2010-03-05 2011-09-09 Intervet International B.V. Recombinant attenuated parvovirus
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
US20140234354A1 (en) * 2013-02-15 2014-08-21 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5b, methods of use and vaccine
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
CN105263953B (zh) * 2014-01-15 2020-01-07 勃林格殷格翰动物保健美国有限公司 猪细小病毒5a、使用方法及疫苗
US10398773B2 (en) 2014-04-17 2019-09-03 Intervet Inc. Porcine parvovirus
UA130511C2 (uk) 2016-11-03 2026-03-11 Бьорінгер Інгельхайм Ветмедіка Гмбх Вакцина проти свинячого парвовірусу й вірусу свинячого репродуктивного й респіраторного синдрому та спосіб її одержання
EP4570264A3 (en) 2016-11-03 2026-01-21 Boehringer Ingelheim Vetmedica GmbH Vaccine against porcine parvovirus
MX2023005182A (es) 2020-11-04 2023-05-15 Intervet Int Bv Parvovirus canino.
CN114957406B (zh) * 2022-05-26 2024-02-02 吉林大学 一种犬细小病毒的三价抗原和三价病毒样颗粒以及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8502399D0 (en) * 1985-01-31 1985-03-06 Akzo Nv Canine parvovirus vaccines
EP1135468B1 (en) * 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
EP1912665B1 (en) * 2005-07-28 2011-01-26 Pfizer Products Inc. Vaccine against feline calicivirus (fcv) comprising a fcv capsid protein or an isolated fcv capsid protein comprising protein sequence seq id no: 13 or protein sequences having at least 95% identity thereto.
SG182206A1 (en) * 2007-06-14 2012-07-30 Univ Oklahoma State Vaccines containing canine parvovirus genetic variants
WO2011107534A1 (en) * 2010-03-05 2011-09-09 Intervet International B.V. Recombinant attenuated parvovirus

Also Published As

Publication number Publication date
JP2018134088A (ja) 2018-08-30
US20120328652A1 (en) 2012-12-27
US9234182B2 (en) 2016-01-12
RU2527157C2 (ru) 2014-08-27
JP2013520977A (ja) 2013-06-10
WO2011107534A1 (en) 2011-09-09
CN102791288B (zh) 2015-02-18
JP2016047053A (ja) 2016-04-07
BR112012021650A2 (pt) 2017-02-21
JP6200155B2 (ja) 2017-09-20
CA2790653C (en) 2019-02-19
EP2542260B1 (en) 2016-03-02
CN102791288A (zh) 2012-11-21
AU2011222910A1 (en) 2012-09-27
AU2011222910B2 (en) 2014-09-18
JP6346143B2 (ja) 2018-06-20
RU2012142309A (ru) 2014-04-10
ES2566033T3 (es) 2016-04-08
EP2542260A1 (en) 2013-01-09
CA2790653A1 (en) 2011-09-09

Similar Documents

Publication Publication Date Title
EP2542260B1 (en) Recombinant Attenuated Parvovirus
JP7661552B2 (ja) ブタサーコウイルス３型免疫原性組成物、その製造方法、およびその使用方法
DK2593136T3 (en) LIVING, WEAKENED PARVOVIRUS
ES2767781T3 (es) Vacunas y diagnóstico de torque teno virus porcino
AU2021375259A9 (en) Canine parvovirus
Chang et al. Enhanced production of Canine parvovirus VP2 protein using improved Baculovirus expression system and its immunogenicity
BR112012021650B1 (pt) Parvovírus recombinante atenuado, vacina para a proteção de animais contra infecção com parvovírus, método para a obtenção do referido parvovírus recombinante e seu uso
ES2783898T3 (es) Parvovirus atenuado vivo
AU2014262215A1 (en) Porcine Torque teno virus vaccines and diagnosis